These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23357204)

  • 41. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
    Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
    Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease.
    Müller-Oehring EM; Sullivan EV; Pfefferbaum A; Huang NC; Poston KL; Bronte-Stewart HM; Schulte T
    Brain Imaging Behav; 2015 Sep; 9(3):619-38. PubMed ID: 25280970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.
    Hashad DI; Abou-Zeid AA; Achmawy GA; Allah HM; Saad MA
    Genet Test Mol Biomarkers; 2011 Dec; 15(12):861-6. PubMed ID: 21699405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
    Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
    Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
    Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
    Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
    Kmiecik MJ; Micheletti S; Coker D; Heilbron K; Shi J; Stagaman K; Filshtein Sonmez T; Fontanillas P; Shringarpure S; Wetzel M; Rowbotham HM; Cannon P; Shelton JF; Hinds DA; Tung JY; ; Holmes MV; Aslibekyan S; Norcliffe-Kaufmann L
    Brain; 2024 Jun; 147(6):1996-2008. PubMed ID: 38804604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease.
    Giladi N; Mirelman A; Thaler A; Bar-Shira A; Gurevich T; Orr-Urtreger A
    J Neurol Sci; 2011 Nov; 310(1-2):17-20. PubMed ID: 21704337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
    Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
    Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gait alterations in healthy carriers of the LRRK2 G2019S mutation.
    Mirelman A; Gurevich T; Giladi N; Bar-Shira A; Orr-Urtreger A; Hausdorff JM
    Ann Neurol; 2011 Jan; 69(1):193-7. PubMed ID: 21280089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
    Silveira-Moriyama L; Guedes LC; Kingsbury A; Ayling H; Shaw K; Barbosa ER; Bonifati V; Quinn NP; Abou-Sleiman P; Wood NW; Petrie A; Sampaio C; Ferreira JJ; Holton J; Revesz T; Lees AJ
    Neurology; 2008 Sep; 71(13):1021-6. PubMed ID: 18809839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.